92 articles
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
A landmark review synthesizes 12 hallmarks of aging, emerging gerotherapeutics, and a new three-tier clinical care model to shift medicine from disease treatment to aging prevention.
GLP-1 receptor agonists used for obesity may deliver an unexpected reproductive benefit: higher testosterone and better sperm.
Analysis of 2,242 NAFLD clinical trials reveals GLP-1 receptor agonists dominate the pipeline, with semaglutide and liraglutide leading the charge.
A landmark 21-year trial finds diet and exercise interventions cut multimorbidity risk by 21% in prediabetic adults — metformin showed no such benefit.
Geroscience pioneer Dr Nir Barzilai explains how intervening in aging biology — not individual diseases — may be medicine's biggest leap.
GLP-1 receptor agonists used for weight loss may also restore male reproductive hormones and improve sperm parameters.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
A 2025 review maps the pathophysiology of CRHM syndrome and spotlights emerging biomarkers that could transform early detection and treatment.
The creator of epigenetic aging clocks breaks down which interventions—omega-3s, multivitamins, vegetables—reliably shift your biological age.
Antag Therapeutics' AT7687 showed strong safety and enhanced weight loss in Phase 1 trials, with a Phase 2a study launching mid-2026.
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
